<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202757</url>
  </required_header>
  <id_info>
    <org_study_id>NeurologyCenter</org_study_id>
    <nct_id>NCT04202757</nct_id>
  </id_info>
  <brief_title>Intravenous Plasma Treatment for Parkinson's Disease</brief_title>
  <acronym>yFFP</acronym>
  <official_title>Intravenous Young Fresh Frozen Plasma (yFFP) Investigational Treatment for Parkinson's Disease - Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Neurology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carolina Longevity Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Neurology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will address a well-known neurological disorder for which there are limited&#xD;
      effective treatments and an urgent need to find an efficacious management that could help&#xD;
      prevent, or at least slow down the progress of this major public health problem.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized double-blind, placebo-controlled trial, designed to evaluate the&#xD;
      efficacy of intravenous [21CFR640.30] Plasma from young, volunteer donors between the ages of&#xD;
      18 - 25 years (yFFP - young Fresh Frozen Plasma) at 12.5 ml/kg in each of two doses, one day&#xD;
      apart (25 ml/kg total).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2018</start_date>
  <completion_date type="Actual">August 8, 2019</completion_date>
  <primary_completion_date type="Actual">August 7, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double-blind, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blinding will be achieved by preparing both yFFP and placebo (0.1% riboflavin in normal saline) solution into identical-sized, masked bags. The riboflavin is added to the saline to achieve indistinguishable color when compared to the yFFP.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>White blood cell and differential count (eosinophils, basophils, neutrophils, lymphocytes and monocytes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>Red blood cell and indices Packed Cell Volume (PCV), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>Hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>Platelets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin G (IgG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>C - reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>Sodium, Potassium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>Urea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory blood-test results of objective serum factors</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>ALT (alanine transaminase), AST (aspartate aminotransferase), GGT (gamma-glutamyl transpeptidase), Bilirubin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Physician assessment</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>Unified Parkinson Disease Rating Scale (UPDRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient assessment</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>Changes in Stanford Presenteeism Scale (SPS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caregiver assessment</measure>
    <time_frame>Two weeks prior to infusion, at one-three-six months post-infusion</time_frame>
    <description>Changes in Kingston Caregiver Stress Scale (KCSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stability of administration</measure>
    <time_frame>At the time of infusions, day 1 and day 2</time_frame>
    <description>Adverse events (if any)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors predicting a beneficial response</measure>
    <time_frame>After the last participant's final contact at 6 months</time_frame>
    <description>Patient Global Impression of change</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Idiopathic Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Young Fresh Frozen Plasma (yFFP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>[21CFR640.30] Plasma from 18 - 25 year old volunteer donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.1% riboflavin in normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>[21CFR640.30] Plasma from 18 - 25 year old volunteer donors</intervention_name>
    <description>12.5 ml/kg intravenous NuPlasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.</description>
    <arm_group_label>Young Fresh Frozen Plasma (yFFP)</arm_group_label>
    <other_name>Young Fresh Frozen Plasma (yFFP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Parkinson's disease&#xD;
&#xD;
          -  Disease duration of 1 to 5 years&#xD;
&#xD;
          -  Failure to respond (poor efficacy or unacceptable side effects) to drugs recommended&#xD;
             for the treatment&#xD;
&#xD;
          -  Willingness to confirm the use of adequate birth control while on the trial will be&#xD;
             required in premenopausal women without evidence for an inability to become pregnant.&#xD;
&#xD;
          -  Willingness to not start any other treatment for Parkinson's or Multiple Sclerosis&#xD;
             during the parallel part of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other significant disease, which in the view of the study doctor may make assessment&#xD;
             of the efficacy of yFFP difficult.&#xD;
&#xD;
          -  Unstable medical conditions.&#xD;
&#xD;
          -  Must weigh at least 45.5 kg. Cannot weigh more than 130 kg.&#xD;
&#xD;
          -  A severe disease state diagnosis&#xD;
&#xD;
          -  Litigation. Patients in litigation will be excluded only if conclusion of that&#xD;
             litigation is imminent during the course of the study.&#xD;
&#xD;
          -  If patient is pregnant or breastfeeding.&#xD;
&#xD;
          -  Complete IgA deficiency.&#xD;
&#xD;
          -  Rare contraindications to yFFP therapy as per summary of product characteristics.&#xD;
&#xD;
          -  Receiving yFFP for other reasons.&#xD;
&#xD;
          -  Ongoing drug or alcohol abuse.&#xD;
&#xD;
          -  Psychiatric disorder that could, in the judgement of the site investigator, interfere&#xD;
             with successful study participation.&#xD;
&#xD;
          -  Unwillingness or inability to complete the study or an inability to understand the&#xD;
             questionnaires being used.&#xD;
&#xD;
          -  Cancer other than basal cell carcinoma within the last 5 years. However, those&#xD;
             patients who have received definitive treatment, such as curative surgery more than 6&#xD;
             months ago, with no known recurrence can be included.&#xD;
&#xD;
          -  A history of hypercoagulable or thrombophilic clotting abnormalities.&#xD;
&#xD;
          -  A history of thrombembolic events: ischaemic stroke, confirmed myocardial infarction,&#xD;
             pulmonary embolism; deep venous thrombosis except where immobility related (for&#xD;
             example, after injury or operation).&#xD;
&#xD;
          -  Unstable angina pectoris.&#xD;
&#xD;
          -  Medications that might react with yFFP such as blood thinners&#xD;
&#xD;
          -  Renal failure or serum creatinine greater than 1.5 times the upper limit of normal at&#xD;
             screening.&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, would make it unsafe&#xD;
             for the patient to participate or which would interfere with assessment of the outcome&#xD;
             measures.&#xD;
&#xD;
          -  Participation in another interventional trial within 3 months of randomization.&#xD;
             Participation in non-interventional studies is not a reason for exclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dian Ginsberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ginstitute of Functional Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Cherches, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Neurology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Neurology Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.youngplasmastudy.com/</url>
    <description>Study assessment-Lab results, documents and references</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected IPD</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Publicly present on YoungPlasmaStudy.com - no expiration date</ipd_time_frame>
    <ipd_access_criteria>Public access</ipd_access_criteria>
    <ipd_url>https://www.youngplasmastudy.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT04202757/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

